Results 101 to 110 of about 46,447 (205)

Maritoclax Overcomes FBW7 Deficiency‐Driven Irinotecan Resistance in Colorectal Cancer by Targeting MCL1

Cancer Medicine
Introduction FBW7, a tumor suppressive E3 ubiquitin ligase frequently mutated in colorectal cancer (CRC), mediates chemotherapy resistance. While irinotecan (via its active metabolite SN38) is a first‐line TOP1 inhibitor for advanced CRC, the mechanistic
Qian Lin, Shuting Liu, Hongfei Jiang, Shasha Wang, Yixin Duan   +4 more
doaj   +1 more source

KRAS Mutations in Cancers: From Undruggable Dilemma to Precision Medicine

MedComm, Volume 7, Issue 10, October 2026.
KRAS‐mutant cancers are therapeutically shaped by both allele identity and tumor context. Direct KRAS inhibition has achieved the greatest clinical success in KRAS G12C‐mutant NSCLC, whereas colorectal cancer often requires EGFR cotargeting and pancreatic cancer remains constrained by stromal and metabolic barriers. Shared resistance mechanisms include
Jiaying Cai, Yimin Wu, Xing Jia, Li Yang, Wenjun Yang, Weishan Lu, Zhiye Huang, Yang Pan, Zixuan Fei, Junnan Ru, Jiazheng Zhao, Jue Shen, Taobo Luo, Da Chen, Haihong Yu, Haihan Deng, Jian Zeng, Wenmei Jiang, Leilei Wu   +18 more
wiley   +1 more source

Efficacy and Safety of Fruquintinib Plus TAS‐102 in Patients With Previously Treated Metastatic Colorectal Cancer: Results From a Single‐Arm, Multi‐Center, Phase II Study

MedComm, Volume 7, Issue 10, October 2026.
This study is the first prospective clinical trial that evaluated the efficacy and safety of fruquintinib combined with TAS‐102 in the later‐line treatment of patients with mCRC. Fruquintinib plus TAS‐102 demonstrated promising efficacy and manageable safety profile in patients with mCRC who had failed at least two standard therapies, supporting its ...
Jianjun Peng, Yong Li, Ling Huang, Jianhua Liu, Jianjun Xiao, Derong Xie, Wei Wang, Zongcheng Zhang, Chengyin Weng, Xiaoshu Chai, Huifen Li, Xiaomei Jiang, Yan Qian, Risheng Zhao, Sile Chen, Zhimin Jiang, Lingdan Le, Xueqin Li, Jianting Long, Haibo Zhang, Chuangqi Chen, Shirong Cai   +21 more
wiley   +1 more source

Evasins: Biology and Therapeutic Potential of Broad‐Spectrum Chemokine Inhibitors

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
ABSTRACT Ticks are haematophagous parasites that rely on uninterrupted bloodmeals for survival and need an effective strategy to suppress the host inflammatory response. Leukocyte recruitment is a chemokine‐mediated hallmark of inflammation, which ticks counteract via anti‐chemokine proteins in their saliva named evasins.
Emilia L. Bialek, Roos Buds, Ingrid Dijkgraaf, Pedro E. Marques   +3 more
wiley   +1 more source

A Three‐Dimensional Culture–Drug Sensitivity Test Predicts MDM2 Inhibitor–Sensitivity in SMARCB1/INI1‐Deficient Tumors

Cancer Science, Volume 117, Issue 10, Page 2852-2862, October 2026.
This study aimed to determine whether personalized selection of effective drugs for SMARCB1/INI1‐deficient tumors is feasible using in vitro drug sensitivity profiling. Drug sensitivity was assessed using a short‐term collagen gel–embedded three‐dimensional drug sensitivity test (3D‐DST) in tumors derived from SMARCB1/INI1‐deficient tumor cell line ...
Hiroaki Goto, Chiyoko Nishime, Takashi Ohtsu, Mieko Ito, Maiko Sagisaka, Takuya Naruto, Norihiko Kitagawa, Mio Tanaka, Masakatsu Yanagimachi, Yukihiko Hiroshima, Junko Takita, Yasuhide Hayashi, Yohei Miyagi   +12 more
wiley   +1 more source

Genomic Evolution and Immune Contexture With Therapeutic Relevance in Pancreatic Neuroendocrine Neoplasms

Cancer Science, Volume 117, Issue 10, Page 2619-2635, October 2026.
Lineage‐dependent immunogenomic landscapes and biologically informed therapy in pancreatic neuroendocrine neoplasms. Pancreatic neuroendocrine neoplasms display lineage‐dependent immunogenomic landscapes, in which genomic alterations, epigenetic states, antigen‐presentation status, immune‐cell infiltration, and suppressive microenvironments co‐evolve ...
Yohei Tabe, Eito Nakagawa, Daisuke Asano, Eriko Katsuta, Daisuke Ban, Shogo Kumagai   +5 more
wiley   +1 more source

Systemic inflammation and prognosis in patients with RAS/BRAF wild‐type metastatic colorectal cancer receiving anti‐EGFR therapy: A real‐world cohort study

Colorectal Disease, Volume 28, Issue 10, October 2026.
Abstract Aim Colorectal cancer outcomes are heterogeneous, so greater prognostic discrimination is needed. In this retrospective real‐world analysis, we assessed the prognostic effect of markers of systemic inflammation in a cohort of patients with RAS/BRAF wild‐type metastatic colorectal cancer (mCRC) who received anti‐EGFR therapy during routine care.
Jordan W. Appleyard, Faye Elliott, Nancy L. Sapanara, Liping Zhang, Uday Kurkure, Jenny F. Seligmann, Nicholas P. West, Kandavel Shanmugam, Philip Quirke, Christopher J. M. Williams, on behalf of the N6 Collaboration   +10 more
wiley   +1 more source

Fruquintinib: Mechanism of Action, Clinical, and Translational Science

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Fruquintinib is a highly selective, oral inhibitor of all three vascular endothelial growth factor receptors (‐1, ‐2, and ‐3) that was approved, including in China, the United States, and the European Union, for the treatment of previously treated metastatic colorectal cancer (mCRC).
Xiaofei Zhou, Arvind Dasari, Jin Li, Caly Chien, Qi Dong, Lucy Chen, Lixian Dong, Neeraj Gupta   +7 more
wiley   +1 more source

Lurbinectedin plus irinotecan in pretreated gastroenteropancreatic neuroendocrine neoplasms: results of a phase II expansion cohort. [PDF]

ESMO Open
Garcia-Carbonero R, Cote GM, Le Cesne A, Antón-Pascual B, Alonso-Gordoa T, Falcon A, Gil-Torralvo A, Martínez S, Kahatt C, Alfaro V, Zubiaur P, Jimenez J, Siguero M, Molina-Cerrillo J.   +13 more
europepmc   +1 more source

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

Clinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju, HeeJae Choi, Shilpa Madari, Annie Carlisle, Ashish Sharma, Christina Kunz, Fenglei Huang   +6 more
wiley   +1 more source